CLINICAL OUTCOMES EverFlex Self-expanding Peripheral Stent

 

DURABILITY II is the first controlled study to focus on treating long, complex lesions and to specifically test the performance of a single long stent in the superficial femoral artery. Read more about the DURABILITY II clinical study in these published, peer-reviewed  journal articles.

DURABILITY II - primary 1 year

The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II).

Matsumura JS, Yamanouchi D, et al.  J Vasc Surg. 2013 Jul;58(1):73-83.

DURABILITY II - primary 3 year

A Single Stent Strategy in Patients with Lifestyle Limiting Claudication:  3-Year Results from the DURABILITY II Trial

Rocha-Singh KJ1, Bosiers M2, et al. Catheter Cardiovasc Interv. 2015 Jul;86(1):164-70.

DURABILITY II - gender 1 year

The Impact of Sex on Angioplasty and Primary Stenting for Femoropopliteal Occlusive Disease: Results of the DURABILITY II Trial.

Tadros RO, Faries PL, et al. Ann Vasc Surg. 2014 Jan;28(1):1-9.

DURABILITY II - gender 3 year

Intermediate Outcomes of Femoropopliteal Stenting in Women: 3-Year Results of the DURABILITY II Trial.

Han DK, Faries PL, et al. Ann Vasc Surg. 2016 Jan;30:110-17. 

DURABILITY 200 - long lesions

Results of the Protégé EverFlex 200-mm-long Nitinol Stent (ev3) in TASC C and D Femoropopliteal Lesions.

Bosiers M, Deloose K, et al. J Vasc Surg. October 2011, 54(4):1042-50.